Literature DB >> 27465505

Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab.

Manish J Butte1, K T Park2, David B Lewis3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27465505      PMCID： PMC5018915          DOI： 10.1007/s10875-016-0318-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  9 in total

1.  Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.

Authors:  Gulbu Uzel; Jordan S Orange; Nina Poliak; Beatriz E Marciano; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

2.  Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation.

Authors:  Eric L Campbell; Walter J Bruyninckx; Caleb J Kelly; Louise E Glover; Eóin N McNamee; Brittelle E Bowers; Amanda J Bayless; Melanie Scully; Bejan J Saeedi; Lucy Golden-Mason; Stefan F Ehrentraut; Valerie F Curtis; Adrianne Burgess; John F Garvey; Amber Sorensen; Raphael Nemenoff; Paul Jedlicka; Cormac T Taylor; Douglas J Kominsky; Sean P Colgan
Journal:  Immunity       Date:  2014-01-09       Impact factor: 31.745

3.  Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease.

Authors:  R Horváth; D Rožková; J Lašťovička; A Poloučková; P Sedláček; A Sedivá; R Spíšek
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

4.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Authors:  William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

5.  Gastrointestinal involvement in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Sergio D Rosenzweig; David E Kleiner; Victoria L Anderson; Dirk N Darnell; Sandra Anaya-O'Brien; Dianne M Hilligoss; Harry L Malech; John I Gallin; Steven M Holland
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

Review 6.  Current concepts of hyperinflammation in chronic granulomatous disease.

Authors:  Nikolaus Rieber; Andreas Hector; Taco Kuijpers; Dirk Roos; Dominik Hartl
Journal:  Clin Dev Immunol       Date:  2011-07-25

7.  Chronic granulomatous disease: a review of the infectious and inflammatory complications.

Authors:  Eunkyung Song; Gayatri Bala Jaishankar; Hana Saleh; Warit Jithpratuck; Ryan Sahni; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2011-05-31

Review 8.  Inflammation and repeated infections in CGD: two sides of a coin.

Authors:  Taco Kuijpers; Rene Lutter
Journal:  Cell Mol Life Sci       Date:  2011-11-15       Impact factor: 9.261

9.  Deficient production of reactive oxygen species leads to severe chronic DSS-induced colitis in Ncf1/p47phox-mutant mice.

Authors:  Tiago Rodrigues-Sousa; Ana Filipa Ladeirinha; Ana Raquel Santiago; Helena Carvalheiro; Bruno Raposo; Ana Alarcão; António Cabrita; Rikard Holmdahl; Lina Carvalho; M Margarida Souto-Carneiro
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240
  9 in total
  9 in total

Review 1.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 2.  Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.

Authors:  Anne E Levine; Hengqi B Zheng; David L Suskind
Journal:  Paediatr Drugs       Date:  2022-04-25       Impact factor: 3.022

3.  Chronic Granulomatous Disease With Inflammatory Bowel Disease: Clinical Presentation, Treatment, and Outcomes From the USIDNET Registry.

Authors:  Brenna LaBere; Maria J Gutierrez; Hannah Wright; Elizabeth Garabedian; Hans D Ochs; Ramsay L Fuleihan; Elizabeth Secord; Rebecca Marsh; Kathleen E Sullivan; Charlotte Cunningham-Rundles; Luigi D Notarangelo; Karin Chen
Journal:  J Allergy Clin Immunol Pract       Date:  2022-01-14

Review 4.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

Review 5.  Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.

Authors:  Beatriz E Marciano; Steven M Holland
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

Review 6.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31

7.  Chronic Granulomatous Disorder-Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level.

Authors:  David M Lowe; Philip J Smith; Fernando Moreira; Sarita Workman; Helen Braggins; Nikolaos Koukias; Matthew S Buckland; Peter Wylie; Stuart A Taylor; Charles D Murray
Journal:  J Clin Immunol       Date:  2019-06-06       Impact factor: 8.317

Review 8.  Recent advances in understanding and treating chronic granulomatous disease.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2017-08-11

9.  Variable Presentation of the CYBB Mutation in One Family, Approach to Management, and a Review of the Literature.

Authors:  Tatyana Gavrilova; Ari Zelig; Diana H Lee
Journal:  Case Rep Med       Date:  2020-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.